Genmab A/S announced top-line results from a Phase II study of the subcutaneous formulation of
ofatumumab in relapsing-remitting multiple sclerosis (RRMS).
A total of 232 subjects with RRMS were randomized in the study. There was a
clear separation from placebo on the cumulative number of new gadolinium
enhancing lesions (active brain lesions) over a period of 12 weeks in subjects
treated with all doses of ofatumumab compared to subjects treated with placebo
[p < 0.001]. For the primary endpoint, analysis of data from weeks 0-12
estimated a 65% reduction in the cumulative number of new T1 gadolinium
enhancing lesions for all doses [p < 0.001]. In weeks 4-12, analyses of data
estimated a >= 90% reduction in the cumulative number of new T1 gadolinium
enhancing lesions for all cumulative doses of ofatumumab >= 30 mg [p < 0.001]...... Read More - http://www.ms-uk.org/emergingtherapies
Positive top-line phase II results of Ofatumumab in MS
Positive top-line phase II results of Ofatumumab in MS
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1296 Views
-
Last post by frodo
-
- 0 Replies
- 960 Views
-
Last post by frodo
-
- 8 Replies
- 7364 Views
-
Last post by Algis
-
- 0 Replies
- 1203 Views
-
Last post by frodo
-
- 0 Replies
- 1592 Views
-
Last post by NHE
-
- 2 Replies
- 4127 Views
-
Last post by DIM
-
- 1 Replies
- 2906 Views
-
Last post by Tif
-
- 0 Replies
- 2305 Views
-
Last post by NHE
-
- 1 Replies
- 1203 Views
-
Last post by Scott1